(Q39473480)

12 September 2017

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers (English)

1 reference

12 September 2017

1 reference

1 reference

D F Brophy

1

1 reference

12 September 2017

D S Israel

2

1 reference

12 September 2017

A Pastor

3

1 reference

12 September 2017

C Gillotin

4

1 reference

12 September 2017

G E Chittick

5

1 reference

12 September 2017

W T Symonds

6

1 reference

12 September 2017

Y Lou

7

1 reference

12 September 2017

B M Sadler

8

1 reference

12 September 2017

R E Polk

9

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

Antimicrobial Agents and Chemotherapy

12 September 2017

1 reference

12 September 2017

44

1 reference

12 September 2017

978-984

1 reference

12 September 2017

4

1 reference

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Pharmacokinetic interaction between ritonavir and clarithromycin

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Noninvasive tests of CYP3A enzymes

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

17 June 2018

HIV-protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

CYP3A4 and the erythromycin breath test.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89801

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test

21 August 2018

1 reference

12 December 2020

Molecular and physical mechanisms of first-pass extraction

1 reference

12 December 2020

1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)

1 reference

12 December 2020

Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial

1 reference

12 December 2020

10.1128/AAC.44.4.978-984.2000

Identifiers

DOI

1 reference

12 September 2017

1 reference

12 September 2017

1 reference